Special Issue

Recent Advances in Nuclear Factor Kappa-B (NF-kB) Inhibitors for Cancer Therapy

Message from the Guest Editor

Nuclear Factor kappa-B is a critical transcription factor regulating numerous target genes. The dysregulation of NF-kB has been linked to developing neurological diseases, immune diseases, and cancer. The upregulation of NF-kB and related pathways promotes the development and progression of cancer from different angles. Additionally, NF-kB can be activated by chemotherapy and radiotherapy, contributing to treatment failure and resistance. Therefore, different synthetic and natural compounds targeting NF-kB have been discovered and shown to be effective in cancer treatment. Here, in this Special Issue entitled "Recent Advances in Nuclear Factor kappa-B inhibitors for Cancer Therapy", we aim to cover reviews and original research articles describing the development and use of NF-kB inhibitors in cancer treatments alone or in combination with other cancer treatment modalities from different perspectives. We also encourage the discussion of the NF-kB-mediated regulation of signaling pathways involving cancer progression in an original review. This could be a starting point for developing new NF-kB inhibitors and related strategies for cancer treatment.

Guest Editor

Dr. Hui-Yen Chuang

Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan

Deadline for manuscript submissions

closed (30 May 2024)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/141162

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

